(NICE) Nice - Ratings and Ratios
AI Cloud Platform, Customer Engagement, Financial Crime, Compliance, Digital Evidence
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 38.6% |
| Value at Risk 5%th | 58.6% |
| Relative Tail Risk | -7.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.10 |
| Alpha | -54.93 |
| CAGR/Max DD | -0.30 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.399 |
| Beta | 0.861 |
| Beta Downside | 0.881 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.92% |
| Mean DD | 25.01% |
| Median DD | 29.37% |
Description: NICE Nice November 03, 2025
NICE Ltd. (NASDAQ:NICE) delivers AI-driven cloud platforms that span three core verticals: customer experience (CXone Mpower), financial-crime compliance (Xceed and data-intelligence suites), and digital evidence management for the criminal-justice system (Evidencentral). The firm’s X-Sight platform targets high-end enterprise customers with a flexible AI-cloud stack, while its subscription-based model now generates roughly 80 % of total revenue, underscoring the shift toward recurring SaaS income.
Key performance indicators from FY 2023 show total revenue of about $1.5 billion, a year-over-year increase of 13 %, and a 28 % YoY growth in cloud-subscription ARR, reflecting strong demand for AI-enabled contact-center solutions. The global contact-center software market is projected to expand at a CAGR of ~23 % through 2029, driven by digital-first consumer expectations and the need for scalable automation.
Regulatory pressure on anti-money-laundering (AML) and fraud detection continues to accelerate adoption of NICE’s compliance suite, especially among mid-size financial institutions that are increasingly required to meet stricter reporting standards. Assuming the firm can sustain its R&D spend (≈15 % of revenue) to stay ahead of rapid AI advances, the upside potential remains tied to the broader AI-software adoption cycle.
For a deeper, data-driven assessment of NICE’s valuation and risk profile, you might explore the analytics platform ValueRay, which aggregates real-time financial metrics and peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (561.1m TTM) > 0 and > 6% of Revenue (6% = 172.8m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 0.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.98% (prev 35.85%; Δ -21.87pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 786.4m > Net Income 561.1m (YES >=105%, WARN >=100%) |
| Net Debt (-331.2m) to EBITDA (815.6m) ratio: -0.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.2m) change vs 12m ago -2.59% (target <= -2.0% for YES) |
| Gross Margin 67.05% (prev 66.70%; Δ 0.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.71% (prev 50.82%; Δ 4.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 103.1 (EBITDA TTM 815.6m / Interest Expense TTM 6.11m) >= 6 (WARN >= 3) |
Altman Z'' 6.18
| (A) 0.08 = (Total Current Assets 1.38b - Total Current Liabilities 980.2m) / Total Assets 5.15b |
| (B) 0.52 = Retained Earnings (Balance) 2.70b / Total Assets 5.15b |
| (C) 0.12 = EBIT TTM 629.9m / Avg Total Assets 5.17b |
| (D) 2.99 = Book Value of Equity 3.86b / Total Liabilities 1.29b |
| Total Rating: 6.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.50
| 1. Piotroski 8.50pt |
| 2. FCF Yield 11.63% |
| 3. FCF Margin 24.70% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -0.41 |
| 6. ROIC - WACC (= 3.35)% |
| 7. RoE 15.29% |
| 8. Rev. Trend 98.91% |
| 9. EPS Trend 98.93% |
What is the price of NICE shares?
Over the past week, the price has changed by +0.86%, over one month by -21.57%, over three months by -22.12% and over the past year by -42.38%.
Is NICE a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NICE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 164 | 54.3% |
| Analysts Target Price | 164 | 54.3% |
| ValueRay Target Price | 86.4 | -18.7% |
NICE Fundamental Data Overview November 23, 2025
P/E Trailing = 11.9443
P/E Forward = 8.5179
P/S = 2.253
P/B = 1.5929
P/EG = 0.8272
Beta = 0.289
Revenue TTM = 2.88b USD
EBIT TTM = 629.9m USD
EBITDA TTM = 815.6m USD
Long Term Debt = 86.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.8m USD (from shortTermDebt, last quarter)
Debt = 86.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -331.2m USD (from netDebt column, last quarter)
Enterprise Value = 6.12b USD (6.49b + Debt 86.9m - CCE 455.9m)
Interest Coverage Ratio = 103.1 (Ebit TTM 629.9m / Interest Expense TTM 6.11m)
FCF Yield = 11.63% (FCF TTM 711.6m / Enterprise Value 6.12b)
FCF Margin = 24.70% (FCF TTM 711.6m / Revenue TTM 2.88b)
Net Margin = 19.48% (Net Income TTM 561.1m / Revenue TTM 2.88b)
Gross Margin = 67.05% ((Revenue TTM 2.88b - Cost of Revenue TTM 949.0m) / Revenue TTM)
Gross Margin QoQ = 66.81% (prev 66.75%)
Tobins Q-Ratio = 1.19 (Enterprise Value 6.12b / Total Assets 5.15b)
Interest Expense / Debt = 7.04% (Interest Expense 6.11m / Debt 86.9m)
Taxrate = 20.37% (37.1m / 181.9m)
NOPAT = 501.6m (EBIT 629.9m * (1 - 20.37%))
Current Ratio = 1.41 (Total Current Assets 1.38b / Total Current Liabilities 980.2m)
Debt / Equity = 0.02 (Debt 86.9m / totalStockholderEquity, last quarter 3.86b)
Debt / EBITDA = -0.41 (Net Debt -331.2m / EBITDA 815.6m)
Debt / FCF = -0.47 (Net Debt -331.2m / FCF TTM 711.6m)
Total Stockholder Equity = 3.67b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.89% (Net Income 561.1m / Total Assets 5.15b)
RoE = 15.29% (Net Income TTM 561.1m / Total Stockholder Equity 3.67b)
RoCE = 16.76% (EBIT 629.9m / Capital Employed (Equity 3.67b + L.T.Debt 86.9m))
RoIC = 12.49% (NOPAT 501.6m / Invested Capital 4.01b)
WACC = 9.14% (E(6.49b)/V(6.58b) * Re(9.19%) + D(86.9m)/V(6.58b) * Rd(7.04%) * (1-Tc(0.20)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 77.81% ; FCFE base≈694.3m ; Y1≈856.5m ; Y5≈1.46b
Fair Price DCF = 326.1 (DCF Value 20.14b / Shares Outstanding 61.7m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 98.93 | EPS CAGR: 17.63% | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.91 | Revenue CAGR: 9.80% | SUE: 0.76 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.62 | Chg30d=-0.532 | Revisions Net=-6 | Analysts=13
EPS next Year (2026-12-31): EPS=11.13 | Chg30d=-2.482 | Revisions Net=-12 | Growth EPS=-9.2% | Growth Revenue=+8.2%
Additional Sources for NICE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle